Share Price and Basic Stock Data
Last Updated: January 22, 2026, 9:32 am
| PEG Ratio | -2.26 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gian Lifecare Ltd operates in the Hospitals & Medical Services sector, with a current market capitalization of ₹10.7 Cr and a share price of ₹10.4. The company has showcased fluctuating revenue trends over the past quarters. Sales stood at ₹2.47 Cr in June 2022, increased to ₹5.09 Cr by December 2022, but then declined to ₹1.55 Cr in March 2023. More recently, the company reported sales of ₹2.43 Cr in June 2023 and ₹2.30 Cr in September 2023, indicating a slight contraction in revenue. Annual sales figures reflect this volatility, with ₹11.41 Cr reported for FY 2023, followed by ₹12.78 Cr in FY 2024, and a trailing twelve-month (TTM) revenue of ₹5.52 Cr. This inconsistency in revenue generation raises concerns about the sustainability of the business model, especially in a competitive healthcare environment where consistent revenue is crucial for growth.
Profitability and Efficiency Metrics
Gian Lifecare Ltd’s profitability metrics reveal significant fluctuations. The operating profit margin (OPM) stood at 16.09%, reflecting some operational efficiency. However, the company recorded a negative operating profit of ₹0.72 Cr in March 2023, followed by a recovery to ₹3.11 Cr in March 2024. The net profit margin for the trailing twelve months was reported at 0.09%, indicating a tight profit structure. Return on equity (ROE) was reported at a low 0.81%, while return on capital employed (ROCE) stood at 3.00%. These figures are considerably lower than typical sector values, suggesting that the company struggles to translate its revenues into meaningful returns. Furthermore, the cash conversion cycle (CCC) was alarming at -555.94 days, indicating inefficiencies in managing working capital, which could jeopardize liquidity and operational stability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Gian Lifecare Ltd exhibits both strengths and weaknesses. As of March 2025, the company reported total borrowings of ₹5.07 Cr against reserves of ₹9.42 Cr, demonstrating a reasonable reserve cushion. However, the interest coverage ratio (ICR) was relatively modest at 2.30x, indicating limited ability to cover interest expenses. The debt-to-equity ratio stood at 0.30, which is manageable but suggests a reliance on borrowed funds. The price-to-book value (P/BV) ratio was recorded at 0.92x, indicating the stock is trading below its book value, which could attract value investors. Nonetheless, the company’s declining net profit—₹0.05 Cr in June 2025—alongside a negative EPS of -0.04, reflects challenges in profitability and could deter potential investors. These financial ratios highlight areas where the company must improve to enhance investor confidence and operational performance.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Gian Lifecare Ltd reveals significant changes over recent quarters. Promoter holdings have steadily decreased from 60.68% in December 2022 to 32.09% by March 2025, indicating a potential loss of confidence among major stakeholders. In contrast, public shareholding has increased from 39.33% to 67.91% in the same period, suggesting growing interest from retail investors. The number of shareholders rose significantly from 526 in December 2022 to 4,285 by March 2025, reflecting an expanding retail base. However, the lack of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) raises concerns about the stock’s attractiveness to larger, more stable investors. This shift in shareholding dynamics may influence stock performance and market perception, as declining promoter stakes could signal potential governance issues or strategic shifts.
Outlook, Risks, and Final Insight
Gian Lifecare Ltd faces a mixed outlook characterized by both opportunities and risks. The company’s ability to stabilize revenues and improve profitability will be crucial for its future performance. Key strengths include a relatively low debt-to-equity ratio and a growing public shareholder base, which may support liquidity and market interest. However, significant risks include the alarming cash conversion cycle, inconsistent revenue trends, and declining promoter confidence, which could hinder operational effectiveness and strategic decision-making. The company must focus on improving operational efficiencies and enhancing its profitability metrics to attract institutional investment and restore stakeholder confidence. In scenarios where operational improvements are realized, Gian Lifecare could potentially leverage its market position in the healthcare sector; conversely, failure to address its financial inefficiencies may lead to further challenges in sustaining growth and profitability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 47.1 Cr. | 141 | 187/120 | 9.61 | 117 | 2.49 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 22.0 Cr. | 20.9 | 33.0/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.7 Cr. | 10.4 | 20.5/7.08 | 119 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 104 Cr. | 55.5 | 98.7/52.2 | 23.0 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 18.7 Cr. | 3.47 | 6.94/3.37 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 24,918.43 Cr | 665.88 | 87.12 | 93.18 | 0.34% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.47 | 2.82 | 5.09 | 1.55 | 2.43 | 2.30 | 3.79 | 4.60 | 1.98 | 1.95 | 1.59 | 1.11 | 0.87 |
| Expenses | 2.45 | 2.33 | 2.80 | 2.27 | 1.92 | 1.97 | 1.55 | 1.49 | 1.76 | 1.72 | 1.11 | 1.12 | 0.73 |
| Operating Profit | 0.02 | 0.49 | 2.29 | -0.72 | 0.51 | 0.33 | 2.24 | 3.11 | 0.22 | 0.23 | 0.48 | -0.01 | 0.14 |
| OPM % | 0.81% | 17.38% | 44.99% | -46.45% | 20.99% | 14.35% | 59.10% | 67.61% | 11.11% | 11.79% | 30.19% | -0.90% | 16.09% |
| Other Income | 0.17 | 0.34 | 0.17 | 0.18 | 0.14 | 0.15 | 0.16 | 0.18 | 0.17 | 0.16 | 0.16 | -0.24 | 0.15 |
| Interest | 0.10 | 0.10 | 0.12 | 0.11 | 0.12 | 0.11 | 0.11 | 0.11 | 0.11 | 0.10 | 0.10 | 0.10 | 0.09 |
| Depreciation | 0.12 | 0.11 | 0.14 | 0.12 | 0.13 | 0.13 | 0.13 | 0.07 | 0.12 | 0.12 | 0.12 | 0.11 | 0.11 |
| Profit before tax | -0.03 | 0.62 | 2.20 | -0.77 | 0.40 | 0.24 | 2.16 | 3.11 | 0.16 | 0.17 | 0.42 | -0.46 | 0.09 |
| Tax % | 0.00% | 14.52% | 13.64% | 18.18% | 35.00% | 16.67% | 24.54% | 29.26% | 37.50% | 11.76% | 9.52% | 4.35% | 33.33% |
| Net Profit | -0.03 | 0.53 | 1.89 | -0.90 | 0.26 | 0.20 | 1.63 | 2.20 | 0.11 | 0.14 | 0.38 | -0.48 | 0.05 |
| EPS in Rs | -0.03 | 0.51 | 1.83 | -0.87 | 0.25 | 0.19 | 1.58 | 2.13 | 0.11 | 0.14 | 0.37 | -0.46 | 0.05 |
Last Updated: December 26, 2025, 7:16 pm
Below is a detailed analysis of the quarterly data for Gian Lifecare Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.87 Cr.. The value appears to be declining and may need further review. It has decreased from 1.11 Cr. (Mar 2025) to 0.87 Cr., marking a decrease of 0.24 Cr..
- For Expenses, as of Jun 2025, the value is 0.73 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.12 Cr. (Mar 2025) to 0.73 Cr., marking a decrease of 0.39 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.14 Cr.. The value appears strong and on an upward trend. It has increased from -0.01 Cr. (Mar 2025) to 0.14 Cr., marking an increase of 0.15 Cr..
- For OPM %, as of Jun 2025, the value is 16.09%. The value appears strong and on an upward trend. It has increased from -0.90% (Mar 2025) to 16.09%, marking an increase of 16.99%.
- For Other Income, as of Jun 2025, the value is 0.15 Cr.. The value appears strong and on an upward trend. It has increased from -0.24 Cr. (Mar 2025) to 0.15 Cr., marking an increase of 0.39 Cr..
- For Interest, as of Jun 2025, the value is 0.09 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.10 Cr. (Mar 2025) to 0.09 Cr., marking a decrease of 0.01 Cr..
- For Depreciation, as of Jun 2025, the value is 0.11 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.11 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.09 Cr.. The value appears strong and on an upward trend. It has increased from -0.46 Cr. (Mar 2025) to 0.09 Cr., marking an increase of 0.55 Cr..
- For Tax %, as of Jun 2025, the value is 33.33%. The value appears to be increasing, which may not be favorable. It has increased from 4.35% (Mar 2025) to 33.33%, marking an increase of 28.98%.
- For Net Profit, as of Jun 2025, the value is 0.05 Cr.. The value appears strong and on an upward trend. It has increased from -0.48 Cr. (Mar 2025) to 0.05 Cr., marking an increase of 0.53 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.05. The value appears strong and on an upward trend. It has increased from -0.46 (Mar 2025) to 0.05, marking an increase of 0.51.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:39 am
| Metric | Mar 2019n n 5m | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.56 | 7.31 | 10.24 | 15.45 | 11.41 | 12.78 | 5.94 | 5.52 |
| Expenses | 0.36 | 5.23 | 7.14 | 9.39 | 9.37 | 6.58 | 4.99 | 4.68 |
| Operating Profit | 0.20 | 2.08 | 3.10 | 6.06 | 2.04 | 6.20 | 0.95 | 0.84 |
| OPM % | 35.71% | 28.45% | 30.27% | 39.22% | 17.88% | 48.51% | 15.99% | 15.22% |
| Other Income | 0.00 | 0.10 | 0.29 | 0.51 | 0.69 | 0.64 | 0.25 | 0.23 |
| Interest | 0.04 | 0.37 | 0.35 | 0.39 | 0.45 | 0.47 | 0.43 | 0.39 |
| Depreciation | 0.02 | 0.26 | 0.29 | 0.33 | 0.50 | 0.46 | 0.47 | 0.46 |
| Profit before tax | 0.14 | 1.55 | 2.75 | 5.85 | 1.78 | 5.91 | 0.30 | 0.22 |
| Tax % | 21.43% | 28.39% | 26.91% | 25.30% | 29.78% | 27.24% | 46.67% | |
| Net Profit | 0.10 | 1.13 | 2.02 | 4.37 | 1.26 | 4.30 | 0.16 | 0.09 |
| EPS in Rs | 1.10 | 1.96 | 4.23 | 1.22 | 4.16 | 0.15 | 0.10 | |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 78.76% | 116.34% | -71.17% | 241.27% | -96.28% |
| Change in YoY Net Profit Growth (%) | 0.00% | 37.58% | -187.50% | 312.44% | -337.55% |
Gian Lifecare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -2% |
| 3 Years: | -25% |
| TTM: | -56% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -32% |
| 3 Years: | -67% |
| TTM: | -98% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | -22% |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 11% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: January 7, 2026, 5:32 pm
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 4.70 | 4.70 | 10.34 | 10.34 | 10.34 | 10.34 |
| Reserves | 0.10 | 2.94 | 4.96 | 3.69 | 4.97 | 9.27 | 9.42 |
| Borrowings | 1.36 | 1.09 | 1.00 | 2.03 | 4.57 | 4.17 | 5.07 |
| Other Liabilities | 6.34 | 3.64 | 4.82 | 7.00 | 8.52 | 8.28 | 10.73 |
| Total Liabilities | 7.81 | 12.37 | 15.48 | 23.06 | 28.40 | 32.06 | 35.56 |
| Fixed Assets | 2.91 | 2.84 | 2.99 | 3.50 | 4.62 | 4.47 | 4.01 |
| CWIP | -0.00 | -0.00 | -0.00 | 0.12 | 0.14 | 0.14 | 0.14 |
| Investments | -0.00 | -0.00 | -0.00 | 0.11 | 0.11 | 0.11 | 0.11 |
| Other Assets | 4.90 | 9.53 | 12.49 | 19.33 | 23.53 | 27.34 | 31.30 |
| Total Assets | 7.81 | 12.37 | 15.48 | 23.06 | 28.40 | 32.06 | 35.56 |
Below is a detailed analysis of the balance sheet data for Gian Lifecare Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 10.34 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.34 Cr..
- For Reserves, as of Mar 2025, the value is 9.42 Cr.. The value appears strong and on an upward trend. It has increased from 9.27 Cr. (Mar 2024) to 9.42 Cr., marking an increase of 0.15 Cr..
- For Borrowings, as of Mar 2025, the value is 5.07 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 4.17 Cr. (Mar 2024) to 5.07 Cr., marking an increase of 0.90 Cr..
- For Other Liabilities, as of Mar 2025, the value is 10.73 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8.28 Cr. (Mar 2024) to 10.73 Cr., marking an increase of 2.45 Cr..
- For Total Liabilities, as of Mar 2025, the value is 35.56 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 32.06 Cr. (Mar 2024) to 35.56 Cr., marking an increase of 3.50 Cr..
- For Fixed Assets, as of Mar 2025, the value is 4.01 Cr.. The value appears to be declining and may need further review. It has decreased from 4.47 Cr. (Mar 2024) to 4.01 Cr., marking a decrease of 0.46 Cr..
- For CWIP, as of Mar 2025, the value is 0.14 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.14 Cr..
- For Investments, as of Mar 2025, the value is 0.11 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.11 Cr..
- For Other Assets, as of Mar 2025, the value is 31.30 Cr.. The value appears strong and on an upward trend. It has increased from 27.34 Cr. (Mar 2024) to 31.30 Cr., marking an increase of 3.96 Cr..
- For Total Assets, as of Mar 2025, the value is 35.56 Cr.. The value appears strong and on an upward trend. It has increased from 32.06 Cr. (Mar 2024) to 35.56 Cr., marking an increase of 3.50 Cr..
Notably, the Reserves (9.42 Cr.) exceed the Borrowings (5.07 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2019n n 5m | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.20 | 0.99 | 2.10 | 4.03 | -2.53 | 2.03 | -4.12 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 860.36 | 78.39 | 73.07 | 42.05 | 103.97 | 137.37 | 335.27 |
| Inventory Days | 4,380.00 | 188.58 | |||||
| Days Payable | 5,266.43 | 1,079.79 | |||||
| Cash Conversion Cycle | -26.07 | 78.39 | 73.07 | 42.05 | 103.97 | 137.37 | -555.94 |
| Working Capital Days | -2,887.41 | -42.44 | -53.82 | -31.42 | -160.27 | -68.83 | -41.84 |
| ROCE % | 37.65% | 31.98% | 46.71% | 12.41% | 29.23% | 2.92% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.04 | 4.02 | 1.03 |
| Diluted EPS (Rs.) | -0.04 | 4.02 | 1.03 |
| Cash EPS (Rs.) | 0.57 | 4.53 | 1.51 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 18.59 | 18.64 | 14.62 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 18.59 | 18.64 | 14.62 |
| Revenue From Operations / Share (Rs.) | 6.41 | 12.69 | 11.53 |
| PBDIT / Share (Rs.) | 1.14 | 6.52 | 2.43 |
| PBIT / Share (Rs.) | 0.53 | 6.00 | 1.95 |
| PBT / Share (Rs.) | 0.03 | 5.56 | 1.54 |
| Net Profit / Share (Rs.) | -0.03 | 4.01 | 1.03 |
| NP After MI And SOA / Share (Rs.) | -0.03 | 4.01 | 1.03 |
| PBDIT Margin (%) | 17.78 | 51.38 | 21.09 |
| PBIT Margin (%) | 8.30 | 47.34 | 16.92 |
| PBT Margin (%) | 0.57 | 43.80 | 13.35 |
| Net Profit Margin (%) | -0.56 | 31.64 | 8.91 |
| NP After MI And SOA Margin (%) | -0.56 | 31.64 | 8.91 |
| Return on Networth / Equity (%) | -0.19 | 21.54 | 7.03 |
| Return on Capital Employeed (%) | 2.35 | 27.51 | 11.55 |
| Return On Assets (%) | -0.10 | 12.72 | 3.76 |
| Long Term Debt / Equity (X) | 0.16 | 0.11 | 0.10 |
| Total Debt / Equity (X) | 0.30 | 0.25 | 0.30 |
| Asset Turnover Ratio (%) | 0.19 | 0.43 | 0.00 |
| Current Ratio (X) | 1.45 | 1.31 | 1.07 |
| Quick Ratio (X) | 1.40 | 1.22 | 0.98 |
| Inventory Turnover Ratio (X) | 8.82 | 2.00 | 0.00 |
| Interest Coverage Ratio (X) | 2.30 | 14.54 | 5.92 |
| Interest Coverage Ratio (Post Tax) (X) | 0.92 | 9.96 | 3.50 |
| Enterprise Value (Cr.) | 16.65 | 24.19 | 16.40 |
| EV / Net Operating Revenue (X) | 2.51 | 1.84 | 1.38 |
| EV / EBITDA (X) | 14.12 | 3.59 | 6.52 |
| MarketCap / Net Operating Revenue (X) | 2.68 | 1.93 | 1.48 |
| Price / BV (X) | 0.92 | 1.31 | 1.16 |
| Price / Net Operating Revenue (X) | 2.68 | 1.93 | 1.48 |
| EarningsYield | 0.00 | 0.16 | 0.06 |
After reviewing the key financial ratios for Gian Lifecare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -0.04. This value is below the healthy minimum of 5. It has decreased from 4.02 (Mar 24) to -0.04, marking a decrease of 4.06.
- For Diluted EPS (Rs.), as of Mar 25, the value is -0.04. This value is below the healthy minimum of 5. It has decreased from 4.02 (Mar 24) to -0.04, marking a decrease of 4.06.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 3. It has decreased from 4.53 (Mar 24) to 0.57, marking a decrease of 3.96.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.59. It has decreased from 18.64 (Mar 24) to 18.59, marking a decrease of 0.05.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.59. It has decreased from 18.64 (Mar 24) to 18.59, marking a decrease of 0.05.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 6.41. It has decreased from 12.69 (Mar 24) to 6.41, marking a decrease of 6.28.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 2. It has decreased from 6.52 (Mar 24) to 1.14, marking a decrease of 5.38.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.53. This value is within the healthy range. It has decreased from 6.00 (Mar 24) to 0.53, marking a decrease of 5.47.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.03. This value is within the healthy range. It has decreased from 5.56 (Mar 24) to 0.03, marking a decrease of 5.53.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.03. This value is below the healthy minimum of 2. It has decreased from 4.01 (Mar 24) to -0.03, marking a decrease of 4.04.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -0.03. This value is below the healthy minimum of 2. It has decreased from 4.01 (Mar 24) to -0.03, marking a decrease of 4.04.
- For PBDIT Margin (%), as of Mar 25, the value is 17.78. This value is within the healthy range. It has decreased from 51.38 (Mar 24) to 17.78, marking a decrease of 33.60.
- For PBIT Margin (%), as of Mar 25, the value is 8.30. This value is below the healthy minimum of 10. It has decreased from 47.34 (Mar 24) to 8.30, marking a decrease of 39.04.
- For PBT Margin (%), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 10. It has decreased from 43.80 (Mar 24) to 0.57, marking a decrease of 43.23.
- For Net Profit Margin (%), as of Mar 25, the value is -0.56. This value is below the healthy minimum of 5. It has decreased from 31.64 (Mar 24) to -0.56, marking a decrease of 32.20.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -0.56. This value is below the healthy minimum of 8. It has decreased from 31.64 (Mar 24) to -0.56, marking a decrease of 32.20.
- For Return on Networth / Equity (%), as of Mar 25, the value is -0.19. This value is below the healthy minimum of 15. It has decreased from 21.54 (Mar 24) to -0.19, marking a decrease of 21.73.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.35. This value is below the healthy minimum of 10. It has decreased from 27.51 (Mar 24) to 2.35, marking a decrease of 25.16.
- For Return On Assets (%), as of Mar 25, the value is -0.10. This value is below the healthy minimum of 5. It has decreased from 12.72 (Mar 24) to -0.10, marking a decrease of 12.82.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.16. This value is below the healthy minimum of 0.2. It has increased from 0.11 (Mar 24) to 0.16, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.30. This value is within the healthy range. It has increased from 0.25 (Mar 24) to 0.30, marking an increase of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.19. It has decreased from 0.43 (Mar 24) to 0.19, marking a decrease of 0.24.
- For Current Ratio (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 1.5. It has increased from 1.31 (Mar 24) to 1.45, marking an increase of 0.14.
- For Quick Ratio (X), as of Mar 25, the value is 1.40. This value is within the healthy range. It has increased from 1.22 (Mar 24) to 1.40, marking an increase of 0.18.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.82. This value exceeds the healthy maximum of 8. It has increased from 2.00 (Mar 24) to 8.82, marking an increase of 6.82.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.30. This value is below the healthy minimum of 3. It has decreased from 14.54 (Mar 24) to 2.30, marking a decrease of 12.24.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.92. This value is below the healthy minimum of 3. It has decreased from 9.96 (Mar 24) to 0.92, marking a decrease of 9.04.
- For Enterprise Value (Cr.), as of Mar 25, the value is 16.65. It has decreased from 24.19 (Mar 24) to 16.65, marking a decrease of 7.54.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.51. This value is within the healthy range. It has increased from 1.84 (Mar 24) to 2.51, marking an increase of 0.67.
- For EV / EBITDA (X), as of Mar 25, the value is 14.12. This value is within the healthy range. It has increased from 3.59 (Mar 24) to 14.12, marking an increase of 10.53.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.68. This value is within the healthy range. It has increased from 1.93 (Mar 24) to 2.68, marking an increase of 0.75.
- For Price / BV (X), as of Mar 25, the value is 0.92. This value is below the healthy minimum of 1. It has decreased from 1.31 (Mar 24) to 0.92, marking a decrease of 0.39.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.68. This value is within the healthy range. It has increased from 1.93 (Mar 24) to 2.68, marking an increase of 0.75.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.16 (Mar 24) to 0.00, marking a decrease of 0.16.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gian Lifecare Ltd:
- Net Profit Margin: -0.56%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.35% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -0.19% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.92
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.4
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 119 (Industry average Stock P/E: 87.12)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.3
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -0.56%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | 7/216(6), Swaroop Nagar, Kanpur Uttar Pradesh 208002 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Arun Kumar Gupta | Managing Director |
| Mrs. Rashika Agarwal | Non Executive Woman Director |
| Mr. Abhiram Saran Agarwal | Ind. Non-Executive Director |
| Mr. Umang Gupta | Ind. Non-Executive Director |
| Mr. Ramesh Yadav | Ind. Non-Executive Director |
| Mr. Shivam Mamgain | Non Executive Director |
FAQ
What is the intrinsic value of Gian Lifecare Ltd?
Gian Lifecare Ltd's intrinsic value (as of 22 January 2026) is ₹7.10 which is 31.73% lower the current market price of ₹10.40, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹10.7 Cr. market cap, FY2025-2026 high/low of ₹20.5/7.08, reserves of ₹9.42 Cr, and liabilities of ₹35.56 Cr.
What is the Market Cap of Gian Lifecare Ltd?
The Market Cap of Gian Lifecare Ltd is 10.7 Cr..
What is the current Stock Price of Gian Lifecare Ltd as on 22 January 2026?
The current stock price of Gian Lifecare Ltd as on 22 January 2026 is ₹10.4.
What is the High / Low of Gian Lifecare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gian Lifecare Ltd stocks is ₹20.5/7.08.
What is the Stock P/E of Gian Lifecare Ltd?
The Stock P/E of Gian Lifecare Ltd is 119.
What is the Book Value of Gian Lifecare Ltd?
The Book Value of Gian Lifecare Ltd is 19.1.
What is the Dividend Yield of Gian Lifecare Ltd?
The Dividend Yield of Gian Lifecare Ltd is 0.00 %.
What is the ROCE of Gian Lifecare Ltd?
The ROCE of Gian Lifecare Ltd is 3.00 %.
What is the ROE of Gian Lifecare Ltd?
The ROE of Gian Lifecare Ltd is 0.81 %.
What is the Face Value of Gian Lifecare Ltd?
The Face Value of Gian Lifecare Ltd is 10.0.